• vcard
D 816.572.4638
F 816.753.1536
  • Education
    • J.D., University of Missouri-Columbia School of Law, 1982
    • B.B.A., cum laude, University of Notre Dame, 1979

Kevin Sweeney is a strategic partner to many emerging and established companies, assisting in the development and implementation of their business, financial, and legal goals. His particular emphasis is serving as an advisor to the top management of life sciences companies.

His understanding and appreciation of the scientific and humanitarian mission of these entities was fostered by early work for entities such as Marion Laboratories, BioTechnica International, and AVAX Technologies. His passion continues to be cultivated by working with numerous entities that advance human health, animal health, plant science, "green" and industrial technologies, and biosafety and homeland security sciences, as well as computer and software technologies. 

One of most exciting endeavors of Kevin’s career was the opportunity to work with Nobel Laureate Dr. Sydney Brenner to co-found the Molecular Sciences Institute in Berkeley, Calif., as one of the leading multidisciplinary basic scientific institutes focused on predictive biology.

As Chair of the Polsinelli Multidisciplinary Life Sciences Practice Group and a senior member of its Corporate Finance Practice Group, Kevin has more than 25 years of experience handling:

  • Mergers and acquisitions
  • Public and private securities offerings
  • Venture capital financing
  • Technology transfer
  • Other complex financial and strategic transactions

Kevin uses his broad contacts in the national scientific, academic, business, and financial communities to assist companies, universities, and other scientific organizations. In leading complex securities, venture capital, private equity, and merger and acquisition transactions, Kevin coordinates and integrates the efforts of investment and commercial bankers, accountants, and other experts.

With extensive experience in the boardroom, Kevin served as a key advisor to the board of directors of numerous public and private companies, advising them on corporate, finance, fiduciary, and SEC issues. He represented independent committees in related-party transactions and investigations of alleged management improprieties, and he advises audit committees, compensation committees, finance committees, and boards of directors.

  • Co-founded the Molecular Sciences Institute in Berkeley, Calif., as one of the leading multidisciplinary basic scientific institutes focused on predictive biology.
  • Represents a number of collegiate sports organizations, handling the negotiation of their television and sponsorship contracts and other financial arrangements, as well as assisting them in corporate and other business matters.
  • Leads initial public offerings and secondary public offers of debt and equity securities, private securities placements, private investment in public equity securities, placement transactions, venture capital investments, and merchant banking transactions, as well as senior secured bank debt facilities and subordinated debt instruments.
  • Implemented complex cross-border, tax-enhanced financial transactions.
  • Handles leveraged buyouts, hostile takeovers and defenses, restructurings, strategic and financially driven transactions, “platform” and “add-on” private equity investments, and acquisitions and divestitures of both public and private companies and divisions and business units.
  • Formed and unwound complex joint ventures and other strategic business relationships and has assisted clients in executing industry roll-up and consolidation strategies.
Publication and Presentations Icon Publications & Presentations
March 13, 2015
eAlerts Alerts
December 17, 2013
eAlerts Alerts
December 11, 2013
eAlerts Alerts
December 3, 2013
eAlerts Alerts
November 27, 2013
eAlerts Alerts
November 22, 2013
video Videos
February 24, 2012
eAlerts Alerts
As the 111th U.S. Congress heads back into session in early September, plenty of issues that impact the life science community await the legislators' attention. This e-blast and corresponding White Paper discusses these issues at length.
September 8, 2009
eAlerts Alerts
Two Polsinelli Shughart attorneys attended the Regional Life Science Policy Public Conference of the Democratic Governors Association (DGA) held June 22-23 in St. Louis. The conference brought together more than 200 representatives of leading life science companies from across the United States to brief five Democratic governors from the central United States on issues critical to the growth of the life science industry in the region.
July 28, 2009
Publication and Presentations Icon Publications & Presentations
Regional Life Science Policy Public Conference - St. Louis, Missouri
June 2009